Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

The antibody-drug conjugate (ADC) arena continues to ring up deals, as Avenzo Therapeutics Inc. signed an exclusive license agreement with Duality Biotherapeutics Inc., whereby Avenzo will develop, ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs for Gliosarcoma does not have sufficient historical data to ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Glioblastoma Multiforme (GBM).

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed ...

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.